Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
AgeX Therapeutics, Inc. (AGE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ... |
| 08/25/2023 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ... |
| 08/24/2023 |
SC 13D/A
| Juvenescence Ltd reports a 78.6% stake in AGEX THERAPEUTICS, INC. |
| 08/21/2023 |
3
| Renondin Jean-Christophe (Director) has filed a Form 3 on AgeX Therapeutics, Inc. |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTE This Fourth Amendment to Amended and Restated Convertible Promissory Note by and between AgeX Therapeutics Inc., a Delaware corporation and a company incorporated in the Isle of Man with company number 018008V and its registered office at 1st Floor Viking House, St Pauls Square, Ramsey, Isle of Man, IM8 1GB is effective as of July 21, 2023 . WHEREAS, Borrower and Lender entered into the Amended and Restated Convertible Promissory Note, dated February 9, 2023 ; WHEREAS, Borrower and Lender wish to further amend the Note. NOW, THEREFORE, in consideration of the premises set forth above and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrower and Lender agree as follows: 1. Definition...",
"SECURED CONVERTIBLE PROMISSORY NOTE This Amendment to Secured Convertible Promissory Note by and between AgeX Therapeutics Inc., a Delaware corporation and a company incorporated in the Isle of Man with company number 018008V and its registered office at 1st Floor Viking House, St Pauls Square, Ramsey, Isle of Man, IM8 1GB is effective as of July 21, 2023 . WHEREAS, Borrower and Lender entered into the Secured Convertible Promissory Note, dated March 13, 2023 ; WHEREAS, Borrower and Lender wish to further amend the Note. NOW, THEREFORE, in consideration of the premises set forth above and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrower and Lender agree as follows: 1. Definitions . Capitalized terms used and not defined in th..." |
|
| 07/21/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ... |
| 06/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 05/23/2023 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Notice of ... |
| 05/18/2023 |
4
| Juvenescence Ltd (10% Owner) has filed a Form 4 on AgeX Therapeutics, Inc.|
Txns:
| Granted 756,429 options to buy
@ $0.661, valued at
$500k
|
|
| 05/12/2023 |
8-K
| Quarterly results |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister... |
| 03/31/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
4
| Juvenescence Ltd (10% Owner) has filed a Form 4 on AgeX Therapeutics, Inc.|
Txns:
| Gifted 16,447,500 shares
@ $0 |
|
| 03/22/2023 |
3
| Juvenescence US Corp. (10% Owner) has filed a Form 3 on AgeX Therapeutics, Inc. |
| 03/22/2023 |
SC 13D/A
| Juvenescence Ltd reports a 78.7% stake in AGEX THERAPEUTICS, INC. |
| 03/15/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"THIS SECURED CONVERTIBLE PROMISSORY NOTE is issued on March 13, 2023 , BY",
"AMENDED AND RESTATED SECURITY AGREEMENT",
"RECITALS",
"Definitions",
"Agreement",
"SECURED CONVERTIBLE FACILITY AGREEMENT This Third Amendment to Secured Convertible Facility Agreement by and between AgeX Therapeutics Inc., a Delaware corporation and Juvenescence Limited, a company incorporated in the Isle of Man with company number 018008V and its registered office at 1st Floor Viking House, St Pauls Square, Ramsey, Isle of Man, IM8 1GB is effective as of March 10, 2023 . WHEREAS, Borrower and Lender, entered into a Secured Convertible Facility Agreement, dated March 30, 2020, as amended by the First Amendment to the Secured Convertible Facility Agreement, dated July 21, 2020 and the Second Amendment to the Secured Convertible Facility Agreement, dated November 12, 2020 ; WHEREAS, the Borrower and Lender wish to amend the Loan Agreement in order to extend the Repayment ..." |
|
| 03/14/2023 |
4
| WEST MICHAEL D (CEO) has filed a Form 4 on AgeX Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,060 shares
@ $0.59, valued at
$625.4
Exercised 3,125 restricted stock units
@ $0 |
|
| 02/10/2023 |
8-K
| Quarterly results |
| 02/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 01/27/2023 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister... |
| 01/27/2023 |
SC 13D/A
| Juvenescence Ltd reports a 72.6% stake in AGEX THERAPEUTICS, INC. |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/15/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/12/2022 |
8-K
| Quarterly results |
| 11/25/2022 |
8-K
| Quarterly results |
|
|
|